Polio health economics: assessing the benefits and costs of polio, non-polio, and integrated activities of the Global Polio Eradication Initiative
Thompson K, Kalkowska D, Badizadegan K
Gates Open Research, 2022; 6(5). doi:10.12688/gatesopenres.13524.1. [version 1; awaiting peer review]
Health economic analyses of secondary vaccine effects: a systematic review and policy insights
Thompson KM, Badizadegan K
Expert Rev Vaccines, 2022:1-16. doi:10.1080/14760584.2022.2017287.
Polio eradication: what kind of world do we want?
Thompson KM
Lancel Infect Dis, 2022; 22(2):161-163. doi:10.1016/S1473-3099(21)00458-8.
A health economic analysis for oral poliovirus vaccine to prevent COVID-19 in the United States
Thompson KM, Kalkowska DA, Badizadegan K
Risk Anal, 2021; 41(2):376-386. doi:10.1111/risa.13614.
Hypothetical emergence of poliovirus in 2020: Part 1. Consequences of policy decisions to respond using nonpharmaceutical interventions
Thompson KM, Kalkowska DA, Badizadegan K
Expert Rev Vaccines, 2021. doi:10.1080/14760584.2021.1891888.
Hypothetical emergence of poliovirus in 2020: Part 2. Exploration of the potential role of vaccines in control and eradication
Thompson KM, Kalkowska DA, Badizadegan K
Expert Rev Vaccines, 2021. doi:10.1080/14760584.2021.1891889.
An updated economic analysis of the global polio eradication initiative
Thompson KM, Kalkowska DA
Risk Anal, 2021; 41(2):393-406. doi:10.1111/risa.13665.
Health and economic outcomes associated with polio vaccine policy options: 2019–2029
Kalkowska DA, Thompson KM
Risk Anal, 2021; 41(2):364-375. doi:https://doi.org/10.1111/risa.13664.
Valuing health outcomes: developing better defaults based on health opportunity costs
Ochalek J, Claxton K, Lomas J, Thompson KM
Expert Rev Pharmacoecon Outcomes Res, 2020:1-8. doi:10.1080/14737167.2020.1812387.
An opportunity to incentivize innovation to increase vaccine safety in the United States by improving vaccine delivery using vaccine patches
Thompson KM, Orenstein WA, Hinman AR
Vaccine, 2020. doi:10.1016/j.vaccine.2020.04.044.
The potential role of using vaccine patches to induce immunity: platform and pathways to innovation and commercialization
Badizadegan K, Goodson JL, Rota PA, Thompson KM
Expert Rev Vaccines, 2020; 19(2):175-194. doi:10.1080/14760584.2020.1732215.
Performance of the United States Vaccine Injury Compensation Program (VICP): 1988–2019
Thompson KM, Orenstein WA, Hinman AR.
Vaccine, 2020. doi: 10.1016/j.vaccine.2020.01.042. Epub 2020 Jan 22.
The National Vaccine Advisory Committee at 30: impact and opportunity
Thompson KM, Gellin BG, Hinman AR, Orenstein WA
Vaccine, 2018; 36(11):1330-1344. doi:10.1016/j.vaccine.2018.01.068.
Systematic review of the incremental costs of interventions that increase immunization coverage
Ozawa S, Yemeke TT, Thompson KM
Vaccine, 2018; 36(25):3641-3649. doi:10.1016/j.vaccine.2018.05.030.
Strengthening the effectiveness of national, state, and local efforts to improve HPV vaccination coverage in the United States: recommendations From the National Vaccine Advisory Committee
National Vaccine Advisory Committee
Public Health Rep, 2018; 133(5):543-550. doi:10.1177/0033354918793629.
Using integrated modeling to support the global eradication of vaccine-preventable diseases
Duintjer Tebbens RJ, Thompson KM
System Dynamics Review, 2018; 34(1-2):78-120. doi:10.1002/sdr.1589.
Key steps forward for maternal immunization: policy making in action
Beigi RH, Omer SB, Thompson KM
Vaccine, 2018; 36(12):1521-1523. doi:10.1016/j.vaccine.2018.02.041.
Evaluation of the 2010 National Vaccine Plan mid-course review: recommendations From the National Vaccine Advisory Committee: Approved by the National Vaccine Advisory Committee on February 7, 2017
National Vaccine Advisory Committee
Public Health Rep, 2017; 132(4):411-430. doi:10.1177/0033354917714233.
Overcoming barriers and identifying opportunities for developing maternal immunizations: recommendations from the National Vaccine Advisory Committee
National Vaccine Advisory Committee
Public Health Rep, 2017; 132(3):271-284. doi:10.1177/0033354917698118.
Characterization of heterogeneity in childhood immunization coverage in central Florida using immunization registry data
Thompson KM, Logan GE, Florida SRT
Risk Anal, 2016; 36(7):1418-26. doi:10.1111/risa.12424.
Framework for optimal global vaccine stockpile design for vaccine-preventable diseases: application to measles and cholera vaccines as contrasting examples
Thompson KM, Duintjer Tebbens RJ
Risk Anal, 2016; 36(7):1487-509. doi:10.1111/risa.12265.
A call for greater consideration for the role of vaccines in national strategies to combat antibiotic-resistant bacteria: recommendations from the National Vaccine Advisory Committee: Approved by the National Vaccine Advisory Committee on June 10, 2015
National Vaccine Advisory Committee
Public Health Rep, 2016; 131(1):11-6. doi:10.1177/003335491613100105.
Overcoming barriers to low HPV vaccine uptake in the United States: recommendations from the National Vaccine Advisory Committee: Approved by the National Vaccine Advisory Committee on June 9, 2015
National Vaccine Advisory Committee
Public Health Rep, 2016; 131(1):17-25. doi:10.1177/003335491613100106.
Assessing the state of vaccine confidence in the United States: recommendations from the National Vaccine Advisory Committee: Approved by the National Vaccine Advisory Committee on June 9, 2015
National Vaccine Advisory Committee
Public Health Rep, 2015; 130(6):573-95. doi:10.1177/003335491513000606.
Managing cholera as a preventable global threat
Thompson KM, Duintjer Tebbens RJ, Chaignat CL, Hill A, Costa AJ, Badizadegan K, Namgyal P, Hutubessy RC
J Vaccines Vaccin, 2013; 4(183):1000183. doi:10.4172/2157-7560.1000183.
Development of investment cases for globally-coordinated management of infectious diseases
Thompson KM, Duintjer Tebbens RJ
J Vaccines Vaccin, 2012; 3(8):164. doi:10.4172/2157-7560.1000164.
Global ICU: Valuing prevention as the new paradigm in global health
Thompson KM
ICU Management, 2012; 12(4):9-11.
Priority shifting and the dynamics of managing eradicable infectious diseases
Duintjer Tebbens RJ, Thompson KM
Manag Sci, 2009; 55(4):650-63. doi:10.1287/mnsc.1080.0965.
Uncertainty and sensitivity analyses of a dynamic economic evaluation model for vaccination programs
Duintjer Tebbens RJ, Thompson KM, Hunink MG, Mazzuchi TA, Lewandowski D, Kurowicka D, Cooke RM
Med Decis Making, 2008; 28(2):182-200. doi:10.1177/0272989X07311752.
The Lyme vaccine: a cautionary tale
Nigrovic LE, Thompson KM
Epidemiol Infect, 2007; 135(1):1-8. doi:10.1017/s0950268806007096.
Emerging issues in vaccine economics: perspectives from the USA
Lieu TA, Thompson KM, Prosser LA, O'Brien MA, Yusuf HR, Shefer AM, Weinstein MC, Rickert DL
Expert Rev Vaccines, 2002; 1(4):433-42. doi:10.1586/14760584.1.4.433.
